Format

Send to

Choose Destination
FEBS Lett. 2013 Jun 27;587(13):1997-2007. doi: 10.1016/j.febslet.2013.05.022. Epub 2013 May 15.

Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors.

Author information

1
Institute of Cytology of Russian Academy of Sciences, Tikhoretsky pr., 4, St. Petersburg 194064, Russia.

Abstract

Polyglutamine diseases are a group of pathologies affecting different parts of the brain and causing dysfunction and atrophy of certain neural cell populations. These diseases stem from mutations in various cellular genes that result in the synthesis of proteins with extended polyglutamine tracts. In particular, this concerns huntingtin, ataxins, and androgen receptor. These mutant proteins can form oligomers, aggregates, and, finally, aggresomes with distinct functions and different degrees of cytotoxicity. In this review, we analyze the effects of different forms of polyQ proteins on other proteins and their functions, which are considered as targets for therapeutic intervention.

PMID:
23684638
DOI:
10.1016/j.febslet.2013.05.022
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center